The present disclosure discloses a preparation method and enrichment method of cyanidin-3-diglucoside-5-glucoside, which relates to the technical field of biochemical industry. Enzyme is used to catalyze the substrate to obtain cyanidin-3-diglucoside-5-glucoside. The temperature of the catalytic reaction is 20-40? C., and the reaction time is 10-30 h. This enzyme can convert various anthocyanins into cyanidin-3-diglucoside-5-glucoside, thereby increasing the content of target anthocyanin. The method is simple to operate, specifically improves the content of cyanidin-3-diglucoside-5-glucoside in the crude extract, and reduces the types of anthocyanins in the crude extract to a certain extent, thereby reducing difficulty of subsequent separation and purification. The use of organic reagents and equipment in the traditional enrichment and purification process is reduced, which is energy-saving and environmentally friendly, and the product obtained by catalysis is of good quality, high yield and high purity.

The present disclosure discloses a preparation method and enrichment method of cyanidin-3-diglucoside-5-glucoside, which relates to the technical field of biochemical industry. Enzyme is used to catalyze the substrate to obtain cyanidin-3-diglucoside-5-glucoside. The temperature of the catalytic reaction is 20-40? C., and the reaction time is 10-30 h. This enzyme can convert various anthocyanins into cyanidin-3-diglucoside-5-glucoside, thereby increasing the content of target anthocyanin. The method is simple to operate, specifically improves the content of cyanidin-3-diglucoside-5-glucoside in the crude extract, and reduces the types of anthocyanins in the crude extract to a certain extent, thereby reducing difficulty of subsequent separation and purification. The use of organic reagents and equipment in the traditional enrichment and purification process is reduced, which is energy-saving and environmentally friendly, and the product obtained by catalysis is of good quality, high yield and high purity.

The present invention provides the use of a separation process to obtain a product composition comprising at least one sophorolipid, wherein the product composition achieves a negative result under the h-CLAT assay according to OECD 442E, wherein the separation process comprises removing a protein component from a starting composition comprising said glycolipid to obtain said product composition, wherein said starting composition achieves a positive result under the h-CLAT assay. The invention further provides a process for obtaining a product composition comprising at least one glycolipid, a product composition obtainable from the process and a personal care formulation or home care formulation comprising the product composition.

The present invention provides the use of a separation process to obtain a product composition comprising at least one sophorolipid, wherein the product composition achieves a negative result under the h-CLAT assay according to OECD 442E, wherein the separation process comprises removing a protein component from a starting composition comprising said glycolipid to obtain said product composition, wherein said starting composition achieves a positive result under the h-CLAT assay. The invention further provides a process for obtaining a product composition comprising at least one glycolipid, a product composition obtainable from the process and a personal care formulation or home care formulation comprising the product composition.

The invention relates to systems and methods for effective production and use of microorganisms and/or the fermentation broth in which they are produced. Advantageously, the system is cost-effective, scalable, quick, versatile, efficacious, and helpful in reducing resistance to chemical compounds and residue that concerns consumers.

The invention relates to systems and methods for effective production and use of microorganisms and/or the fermentation broth in which they are produced. Advantageously, the system is cost-effective, scalable, quick, versatile, efficacious, and helpful in reducing resistance to chemical compounds and residue that concerns consumers.

Derivatives of PSAs are synthesized, in which a reducing and/or non-reducing end terminal sialic acid unit is transformed into a N-hydroxysuccinimide (NHS) group. The derivatives may be reacted with substrates, for instance substrates containing amine or hydrazine groups, to form non-cross-linked/crosslinked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs, peptides or proteins or drug delivery systems.

Derivatives of PSAs are synthesized, in which a reducing and/or non-reducing end terminal sialic acid unit is transformed into a N-hydroxysuccinimide (NHS) group. The derivatives may be reacted with substrates, for instance substrates containing amine or hydrazine groups, to form non-cross-linked/crosslinked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs, peptides or proteins or drug delivery systems.

Derivatives of PSAs are synthesised, in which a reducing and/or non-reducing end terminal sialic acid unit is transformed into a N-hydroxysuccinimide (NHS) group. The derivatives may be reacted with substrates, for instance substrates containing amine or hydrazine groups, to form non-cross-linked/crosslinked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs, peptides or proteins or drug delivery systems.

Derivatives of PSAs are synthesised, in which a reducing and/or non-reducing end terminal sialic acid unit is transformed into a N-hydroxysuccinimide (NHS) group. The derivatives may be reacted with substrates, for instance substrates containing amine or hydrazine groups, to form non-cross-linked/crosslinked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs, peptides or proteins or drug delivery systems.